No. As of September 2026, Altimmune, Inc. (ALT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 7.08% / 30% · (Cash+Inv) / Mkt Cap (36m) 96.4% / 30% · Interest income / Revenue 481900000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 7.08% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 53.2% / 33% · Receivables / Mkt Cap (36m) 0.74% / 49% · Interest income / Revenue 481900000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 7.08% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 53.2% / 33.33% · Receivables / Mkt Cap (24m) 0.74% / 33.33% · Interest income / Revenue 481900000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 8.47% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 73.0% / 33.33% · Receivables / Avg Assets (4Q) 0.55% / 33.33% · Interest income / Revenue 481900000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 7.12% / 33.33% · (Cash+ST Inv) / Total Assets 53.5% / 33.33% · (Cash+Recv) / Total Assets 54.2% / 33.33% · Interest income / Revenue 481900000.0% / 5% | Fail |
No. As of September 2026, Altimmune, Inc. (ALT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Altimmune, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 481900000.0% of each dividend: Altimmune, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
Altimmune, Inc. (NASDAQ: ALT) is a Healthcare company (Biotechnology) with a market capitalization of $298M. The Maz Rating grades it against the other companies in its sector.
Altimmune, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.53, Altimmune, Inc. trades at 11376.0x sales and 0.7x book value. Over the last twelve months it generated about $26171 of revenue and a net loss of $141M. It runs a gross margin of -238196.2%, an operating margin of -442580.8% and a net margin of -401361.5%. It shows return on equity of -29.3%, return on invested capital of -23.8% and a free cash flow yield of -34.6%. On the balance sheet: a debt-to-equity ratio of 0.08 and a current ratio of 23.93. Over the past 52 weeks the share price ranged from $1.50 to $6.44, with a beta of 0.18.
Altimmune, Inc. does not currently pay a dividend.
15 Wall Street analyst ratings cover the stock: 12 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.